Asthma refers to the narrowing of the airway of lungs caused by inflammation in the air passage resulting from both genetic and environmental influences. Allergic asthma leads to allergies when the immune system overreacts to the presence of a harmless substance known as allergen. Some people may develop breathing problems from inhaling allergens. It occurs when the airways swell as part of an allergic reaction. Allergic asthma is the most common form of asthma and is triggered by inhaled allergens, such as dust mite allergen, pet dander, pollen, mould, resulting in asthma symptoms. The symptoms of allergic asthma include coughing, wheezing, shortness of breath or rapid breathing and chest tightness. Triggers cause inflammation (swelling and redness) in the airway. The drug candidates of allergic asthma pipeline include but are not limited to, ASM8, ARRY-502 and SB010.
Some of the companies having drugs for allergic asthma in pipeline are Pharmaxis, sterna biologicals GmbH & Co. KG and Array BioPharma.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.